Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 99Genitourinary 53Thoracic 22Head & Neck 21Sarcoma 18Other hematologic neoplasm 17Dermatologic 16Breast 15Endocrine 12Gynecologic 9CNS 8Other solid neoplasm 5Lymphoid 5Tumor-Agnostic 4Myeloid 4NET 2Plasma cell 1

Conditions

Neuroendocrine Tumors 2Vipoma 1Somatostatinoma 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Islet Cell 1

Interventions

lutetium Lu 177 dotatate 18Everolimus 13Temozolomide 12Nivolumab 10pembrolizumab 9cabozantinib 8Capecitabine 8Sunitinib 7lenvatinib 5Magnetic Resonance Spectroscopy 5Etoposide 5lanreotide 4gallium Ga 68 dotatate 4Specimen Handling 4Ipilimumab 4Cisplatin 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4telotristat ethyl 3surufatinib 3pazopanib 3avelumab 3Octreotide 3Injections 3Fluorodeoxyglucose F18 3Cyclophosphamide 3Bevacizumab 3sintilimab 2fosbretabulin 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Sorafenib × NET × Clear all
NCT00605566 2019-02-19

Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors

University Health Network, Toronto

Phase 2 Completed
22 enrolled 10 charts
EndocrineNET

Neuroendocrine Tumors

NCT00131911 2014-11-17

Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Completed
93 enrolled 10 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡